What is OncoTartis?
OncoTartis is dedicated to creating innovative small molecule drugs through its proprietary TARTIS discovery approach. The company's pipeline is highlighted by OT-82, a NAMPT inhibitor currently in a Phase 1/2a clinical study for hematological malignancies. This strategic focus on specific cancer types, including breast, prostate, ovarian, melanoma, and blood cancers, positions OncoTartis within the competitive oncology drug development landscape. The company's efforts are primarily directed towards oncologists and healthcare professionals.
How much funding has OncoTartis raised?
OncoTartis has raised a total of $6.1M across 2 funding rounds:
Unspecified
$6M
Debt
$57K
Unspecified (2017): $6M with participation from Pharmstandard International S.A.
Debt (2021): $57K led by PPP
Key Investors in OncoTartis
Pharmstandard International S.A.
Pharmstandard International S.A. is a significant player in the pharmaceutical manufacturing and wholesale sector, with a notable presence in Russia. Their involvement in biotechnological research and medical equipment production suggests a strategic interest in advancing healthcare solutions.
What's next for OncoTartis?
The recent infusion of substantial expansion capital signals a critical growth phase for OncoTartis. This investment is expected to accelerate the clinical development of OT-82 and potentially expand the company's research into other targeted cancer therapies. With a clear focus on advancing its lead candidate through clinical trials, OncoTartis is poised to further its mission of delivering novel treatments for challenging oncological conditions. The company's trajectory suggests a continued emphasis on strategic partnerships and further funding rounds to support its long-term development goals.
See full OncoTartis company page
